Esperion Investor Day: Lighting the Way for Phase 2b Results

September 5, 2014
Tim Mayleben
President and Chief Executive Officer

On July 29th, Esperion held its inaugural investor day in New York City, with a tightly-packed agenda for the half-day event that included presentations from several of the world’s leading experts in their respective fields.  It was an exciting and informative day! Dr. James McKenney, President and CEO of National Clinical Research, and Professor Emeritus… Read More

“The IPO Age: Onward and Upward” — Insights from the BioCentury TV Roundtable

May 7, 2014
Tim Mayleben
President and Chief Executive Officer

Recently, I had the pleasure of participating in a roundtable, “The IPO Age: Onward and Upward,” to review how the recent spate of biotech IPOs belies the earlier struggle to finance trials and product development. I was joined by fellow biotech CEOs, Jeff Abbey of Argos and Scott Koenig of MacroGenics, for an engaging and… Read More

ACC.14: Spotlighting the Importance of Finding New Therapies for Statin Intolerant Patients

April 21, 2014
Roger Newton, PhD, FAHA
Executive Chairman and Chief Scientific Officer

Late last month, the American College of Cardiology (ACC) held its 63rd Annual Scientific Session & Expo with more than 13,000 cardiovascular experts coming together in Washington, D.C. As I have for many years, I traveled to ACC.14 with my Esperion colleagues to hear firsthand the latest research findings in the prevention, diagnosis and treatment… Read More